Dose-response Study of Apremilast in Women and Men With Alcohol Use Disorder

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

July 31, 2030

Study Completion Date

July 31, 2030

Conditions

Alcohol Use Disorder

Interventions

DRUG

Apremilast 60mg

Apremilast 60mg/day

DRUG

Apremilast 90mg

Apremilast 90mg/day

OTHER

Placebo

Trial Locations (1)

Yale University, New Haven

All Listed Sponsors

collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

Yale University

OTHER